Spiro Derivatives Modulating CRTH2 Activity for Allergic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases and inflammatory dermatoses, such as asthma and atopic dermatitis, often have limited efficacy and are associated with side effects, highlighting the need for new therapeutic agents that effectively modulate CRTH2 activity.
Innovation Solution
Development of spiro derivatives represented by Formula (I), which are used as pharmaceutical active compounds to treat and prevent allergic diseases and inflammatory dermatoses by modulating CRTH2 activity, including allergic asthma, rhinitis, and inflammatory dermatoses like atopic dermatitis, through the administration of specific spiro derivatives in pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (antihistamines, corticosteroids, leukotriene modulators) are used to treat allergic diseases and inflammatory dermatoses, then these diseases can be managed to some extent, but the treatments have limited efficacy and are associated with side effects
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified molecular structures (spiro derivatives with specific R1, R2, R3, R4, R5, R6 substituents) that target CRTH2 receptor. This changes the pharmacological parameters of the treatment, achieving better efficacy against allergic diseases and inflammatory dermatoses while reducing side effects compared to existing therapies like corticosteroids and antihistamines.
2Ease of manufacture
If current pharmaceutical agents are used to treat allergic diseases, then some therapeutic effect is achieved, but the usefulness is often limited by side effects and low efficacy
Solution Approach 1:
The patent employs composite materials principle by creating spiro derivative compounds that combine multiple functional groups (indole, pyrrolidine, oxindole moieties with various substituents) into a single molecular structure. This composite molecular design enables the compound to simultaneously achieve high efficacy in treating allergic diseases and inflammatory dermatoses while maintaining favorable pharmacological properties and reduced side effects.
3Reliability
If new therapies are developed to effectively treat allergic diseases and inflammatory dermatoses, then efficacy can be improved, but the complexity of developing and administering new therapeutic agents increases
Solution Approach 1:
The patent applies the extraction principle by specifically targeting and isolating the CRTH2 receptor as the therapeutic target, separating it from the complex network of inflammatory pathways. By designing spiro derivatives that selectively modulate CRTH2 activity rather than broadly suppressing inflammation, the treatment achieves high efficacy with reduced complexity in terms of mechanism of action and potentially simpler administration protocols compared to broad-spectrum anti-inflammatory agents.
Data Source
AI summary
The present invention is related to the use of spiro derivatives of Formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of spiro derivatives for the modulation of CRTH2 activity.